Wolverine Trading
ESPR

Wolverine Trading’s Esperion Therapeutics ESPR Stock Holding History

Wolverine Trading’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$139K Buy
52,700
+27,500
+109% +$53.2K ﹤0.01% 5088
2025
Q2 		$25K Buy
25,200
+300
+1% +$300 ﹤0.01% 4453
2025
Q1 		$37.4K Sell
24,900
-5,100
-17% -$9.4K ﹤0.01% 4481
2024
Q4 		$64.5K Buy
30,000
+11,500
+62% +$26.8K ﹤0.01% 4920
2024
Q3 		$31.1K Sell
18,500
-10,200
-36% -$20.6K ﹤0.01% 4594
2024
Q2 		$63.7K Buy
+28,700
New +$67.5K ﹤0.01% 4179
2023
Q4 		– Sell
-14,800
Closed -$14.5K – 4669
2023
Q3 		$14.5K Buy
14,800
+4,000
+37% +$5.79K ﹤0.01% 4353
2023
Q2 		$14.5K Sell
10,800
-1,700
-14% -$2.37K ﹤0.01% 4116
2023
Q1 		$21K Sell
12,500
-34,600
-73% -$179K ﹤0.01% 3994
2022
Q4 		$293K Buy
+47,100
New +$337K ﹤0.01% 2779
2021
Q4 		– Sell
-25,600
Closed -$318K – 6140
2021
Q3 		$318K Buy
+25,600
New +$373K ﹤0.01% 4617
2021
Q2 		– Sell
-19,200
Closed -$527K – 6194
2021
Q1 		$527K Buy
+19,200
New +$566K ﹤0.01% 3625
2020
Q2 		– Sell
-13,400
Closed -$455K – 4731
2020
Q1 		$455K Sell
13,400
-19,100
-59% -$1.01M ﹤0.01% 2763
2019
Q4 		$1.94M Buy
32,500
+5,300
+19% +$238K ﹤0.01% 1857
2019
Q3 		$1.03M Buy
27,200
+10,800
+66% +$428K ﹤0.01% 1961
2019
Q2 		$763K Buy
16,400
+1,800
+12% +$84.5K ﹤0.01% 2289
2019
Q1 		$586K Sell
14,600
-5,800
-28% -$260K ﹤0.01% 2589
2018
Q4 		$901K Buy
+20,400
New +$983K ﹤0.01% 2064
2018
Q3 		– Sell
-42,100
Closed -$3.04M – 5154
2018
Q2 		$3.04M Hold
42,100
– – 0.01% 1241
2018
Q1 		$3.04M Buy
42,100
+9,400
+29% +$690K 0.01% 1241
2017
Q4 		$2.15M Buy
32,700
+2,500
+8% +$135K 0.01% 1487
2017
Q3 		$1.51M Sell
30,200
-8,500
-22% -$410K 0.01% 1537
2017
Q2 		$1.83M Buy
+38,700
New +$1.42M 0.01% 1292

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Wolverine Trading's ESPR Position: Q3 2025 in Review

Wolverine Trading sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 10,805 shares — an estimated $20.9K sold.

Wolverine Trading first reported a position in ESPR in Q2 2017 and held it in 6 quarters. The position peaked at $1.89M in Q2 2018. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Wolverine Trading reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wolverine Trading sold 10,805 Esperion Therapeutics shares in Q3 2025, an estimated $20.9K.
  • Wolverine Trading first reported a position in Esperion Therapeutics in Q2 2017 and held it in 6 quarters.
  • Wolverine Trading's Esperion Therapeutics position peaked at $1.89M in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.